Investor Overview

STOCK QUOTE

Exchange
NASDAQ GS
Last Price
$6.69
Change (%)
+0.49 (7.90%)

INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of patients' lives.

Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, SUBSYS®, a sublingual Fentanyl spray for breakthrough cancer pain launched in March of 2012, and SYNDROS®, the first and only FDA-approved liquid dronabinol for loss of appetite in AIDS patients and nausea and vomiting caused by anti-cancer medicine (chemotherapy). Please see full prescribing information for SUBSYS® and SYNDROS® including the boxed warning.

Our product pipeline is aimed at addressing conditions with unmet medical needs, such as refractory pediatric epilepsy (including childhood absence epilepsy and infantile spasms), the genetic disorder Prader-Willi syndrome, anorexia-associated weight loss in cancer patients, agitation in Alzheimer's disease, migraine, anaphylaxis (severe allergic reaction), acute pain, opioid dependence and reversal of opioid-induced respiratory depression.

 

Recent News

Dec 07 2017
INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis
Using standard intramuscular injection as comparator, company’s Phase 1 clinical trial enrolls first patient PHOENIX, Dec. 07, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that it has started a pr... 
Dec 06 2017
FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics
Novel formulation of partial opioid offers potential benefits compared to current alternatives PHOENIX, Dec. 06, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that its New Drug Application (NDA) fo... 
Nov 27 2017
INSYS Therapeutics, Inc. to Participate in the 29th Annual Piper Jaffray Healthcare Conference
PHOENIX, Nov. 27, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”) announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will participate in the 29th Annu... 
see all news

Receive Email Alerts

Sign Up Now

Upcoming Events

There are currently no events scheduled.

see all events